

Place of Liver Transplant in Alcoholic Hepatitis

Khalid Rasheed^{1*}, Sumant Arora¹, Ronak V Patel¹, Rehan Sarmad¹ and Gary A Abrams²

¹Department of Medicine, University of Alabama at Birmingham, Montgomery Internal Medicine Residency Program, 2055 East South Blvd, Suite 202, Montgomery, USA

²Division of Gastroenterology, Montgomery Internal Medicine Residency Program, 2055 East South Blvd, suite 806, Montgomery, USA

*Corresponding author: Khalid Rasheed, MD, Department of Medicine, University of Alabama at Birmingham, Montgomery Internal Medicine Residency Program, 2055 East South Blvd, Suite 202, Montgomery, AL 36116, USA, Tel: 334-551-2012; Fax: 334-284-9020; E-mail: khalidra@uab.edu

Rec date: July 21, 2015; Acc date: August 29, 2015; Pub date: September 5, 2015

Copyright: © 2015 Rasheed K, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License; which permits unrestricted use; distribution; and reproduction in any medium; provided the original author and source are credited.

Abstract

In the United States and Europe, after viral hepatitis, alcoholic liver disease (ALD) is the second most commonly recognized indication for liver transplantation. Issues of conflicting data on six-month abstinence, eligibility criteria for selection of patients, and clarity of definition of post-transplant relapse are still under debate. Despite high early mortality, acute alcoholic hepatitis continues to be a contraindication to transplant despite data demonstrating the successful outcome of liver transplantation in these individuals. Disagreements arise due to the trepidation that these patients may relapse resulting in damage to the graft or non-compliance causing graft rejection. However, 1-year, 3-year, and 5-year patient and graft survival after transplant are comparable to transplantation for other etiologies. Studies have revealed that pre-OLT abstinence is a poor forecaster of post-OLT relapse. Life-threatening liver failure can potentially develop in this time frame, resulting in augmentation in waitlist mortality. Due to the paucity of available livers for donation, it is considered by many authorities to be obligatory to choose candidates with a lesser risk for relapse with the utilization of existing prophetic factors and mandatory clinical and psychological pre-transplant evaluations by substance abuse specialists and psychiatrists/psychologists. There is concern that if amendments in guidelines for liver transplantation are made for these patients, it may lead to a significant decline in willingness to donate. However, patients with fulminant hepatic failure due to intentional acetaminophen poisoning or due to intravenous-drug use-related acute hepatitis-B virus infection, did not come across this issue. Therefore, a further exploration into this field and these issues is needed.

Keywords: Alcoholic hepatitis; Liver transplant; Recidivism

Introduction

Severe alcoholic hepatitis (AH) can result in death within two months of the acute illness and, despite early successful liver transplantation for these individuals, the treatment approach remains controversial [1,2]. Although data regarding the six-month abstinence rule as a predictor of long-term sobriety is controversial, such abstinence is usually requisite before patients with severe alcoholic hepatitis are considered for liver transplantation [3]. However, the United Network for Organ Sharing (UNOS) and the French Consensus Conference does not regard this to be a formal guideline [4]. Patients whose hepatitis is not responding to medical therapy have a six-month survival rate of approximately 30%. The Lille model enables early identification of patients unlikely to respond to medical treatment [5,6]. Strict application of the six-month abstinence rule may be detrimental to such patients, as 70 to 80% of them die within that period [7,8]. Taken together, all available treatment options, including early transplantation in this high-risk group of patients, may be considered as recommended by the latest French consensus [4].

Epidemiology and Mortality

Although AH is an acute condition, nearly 50% of patients have established cirrhosis at the time of clinical presentation [9]. AH is a distinct clinical entity caused by chronic alcohol abuse carrying poor prognosis with a 28-day mortality ranging from 30% to 50% [10]. The amount of alcohol consumption that places an individual at risk of developing AH is unknown. However, most patients with AH drink

more than 100 gm/d (which corresponds to six to seven alcoholic drinks per day where one drink contains 13-15 gm of alcohol, with 150-200 gm/d being common) [11,12]. The typical age at presentation of AH is between 40 and 50 years, with the majority occurring before the age of 60 years [13,14]. The precise incidence of AH is unknown, although a prevalence of approximately 20% was noted in a cohort of 1604 patients with alcoholism who underwent liver biopsy [11]. The true prevalence of AH is difficult to assess because AH may be completely asymptomatic and often remains undiagnosed. About 10 to 35% of all alcoholics have changes consistent with AH and the estimated number of AH patients in the United States may be nearly 5 million [15].

Overall mortality is 15% at day 30 and 39% at 1 year. However, it varies with disease severity with about 20% in mild cases, and between 30% to 60% in severe AH [16]. In a study on a cohort of patients with AH followed for over 4 years, survival was about 58% in uncomplicated AH, and 35% in AH with cirrhosis. The probability of developing cirrhosis in patients with AH is approximately 10% to 20% per year, and approximately 70% of patients with AH will ultimately develop cirrhosis [17,18]. Recent analysis confirmed patients without treatment and with a Hepatitis Discriminant Factor score of 32 or higher and/or the presence of encephalopathy have a 28-day survival of about 68% [19]. At least 3 studies have suggested that the Model for End Stage Liver Disease (MELD) score may also predict mortality in patients hospitalized for AH [20-22]. A MELD score of 21 had a sensitivity of 75% and specificity of 75% for predicting 90-day mortality. As suggested, the rates of deaths related to AH did not increase over the 24-year period [23]. However, this may signify an incomplete picture as AH is often misdiagnosed and the true burden of

AH related deaths may be undervalued [15]. Additional studies are required to assess the actual incidence and prevalence of AH along with strategies to decrease the mortality rates in severe cases.

Six Months Abstinence Rule

Patients with alcoholic liver disease (ALD) classically have taken a back seat when it comes to allocation for liver transplantation. This stemmed from the belief that ALD transplant recipients would relapse and that these patients are less deserving of scarce donor organs because of their connivance in causing liver damage [24-27].

Currently, Pre-OLT (Orthotropic liver transplant) abstinence is obliging, but setting a fixed period of abstinence remains divisive [28-32]. The advocated standard is a 'six-month abstinence' rule but its validity to lessen the risk of relapse remains questionable as its selection is completely random being driven by custom and practice rather than evidence-based [33,34]. Karim et al. confirmed that duration of abstinence for at least six months was the strongest predictor of recidivism after OLT. Based on this, a minimum of six months of abstinence before OLT would appear to be reliable [35,36]. Further, few authors even argued that patients with alcohol abstinence shorter than six months should be excluded from OLT programs since recurrence and death rates were increased in this subgroup of patients [35].

However, the six-month pre-transplant abstinence rule did not emerge as a predictor of recidivism as suggested by a pooled analysis of 32 studies. Such pre-OLT abstinence inaccurately predicts post-OLT relapse [36-39] and life-threatening liver failure can potentially develop in this period, resulting in heightened waitlist mortality [34,40,41]. Rather, factors such as patient's insight, social support, and comorbid psychiatric disorders were stronger predictors. Therefore, the six-month abstinence rule should be treated as a recovery period and not as a predictor of recidivism risk. It may allow some patients enough time to recuperate their liver to an extent that they may no longer require OLT. It may also serve to buy professionals time for assessing patients for potential of compliance with post-transplant requirements.

In patients with severe AH with or without advance ALD, the pre-OLT abstinence period should be decreased, especially if the liver function is rapidly deteriorating, at least in those who are being strictly followed by an alcohol addiction unit, to help reduce organ wastage [30,42]. Evidence from the UNOS database, single-center studies and the prospective data presented by Mathurin et al., reflected that early liver transplantation clearly improves the probability of six-month survival in patients who continue to deteriorate after three months of abstinence or those who fail medical therapy [40,41]. Thus abstinence alone should not be the sole deciding factor for OLT since many patients present beyond the chance for natural liver recovery and transplant is their only option.

Despite this, patients with AH, particularly in the United States and United Kingdom, remain excluded from the indications for liver transplantation. Therefore, the six-month abstinence rule remains an insurmountable barrier [29,31], except in isolated cases. This will probably be followed until a new consensus emerges.

McCallum and Masterton identified multiple factors consistently associated with recidivism such as younger age, associated polysubstance abuse, lack of social support, family history of alcohol abuse in a first-degree relative, poor response to previous rehabilitation programs, and noncompliance. These factors can guide in carefully

selecting a subset of the patients with acute severe AH who might benefit from LT [43]. Equally important is to deal with pre-existing psychiatric conditions before and after OLT and provide unrelenting support to prevent relapse to achieve sustained abstinence. Thus, efforts are needed in the form of multicenter randomized trials to develop the best criteria for abstinence prior to OLT. This will help identify and recognize candidates who would benefit the most and are the least at risk of recidivism to harmful drinking. It will also help ensure optimal utilization of available organs for AH as that for acute liver failure secondary to other causes [43].

Role and effectiveness of available medical therapy

The American Association of Study of Liver Diseases (AASLD) guidelines suggest a MELD score cutoff of 18 to predict severe AH and as the measure for initiating medical treatment [9]. Many agents have been tried for the treatment of severe AH. No long term survival benefit has been proven with corticosteroids [43]. Side effects including fatal gastrointestinal bleeding and sepsis in patients with severe AH preclude their use [44,45]. Unfortunately, many of the early trials on corticosteroids were small with limited statistical power but they suggested an encouraging role in patients with acute AH and hepatic encephalopathy without active gastrointestinal bleeding, by reducing short-term mortality [46].

Follow up studies failed to confirm these beneficial results [47]. Further, the efficacy of corticosteroids has not been evaluated in patients with concomitant pancreatitis, gastrointestinal bleeding, renal failure, or active infection. In one report, patients with a Maddrey score of greater than 54 who received corticosteroids had higher mortality than those who had not received them [45]. According to the AASLD and the European Association for the Study of the Liver (EASL), pentoxifylline is recommended for severe AH, when there are contraindications to corticosteroids like sepsis and GI bleed [48,49]. Although there has been reduced incidence of fatal hepatorenal syndrome with pentoxifylline compared with placebo, no survival benefit at one-month was demonstrated [50]. In addition, no difference was found between trials of pentoxifylline versus corticosteroids versus combination therapy [51,52]. More studies are required to reach a consensus on the efficacy and role of medical therapy and consideration should be given to early liver transplant in targeted groups of severe AH patients with high mortality.

Early Liver Transplant

Patients with severe AH pose a particular challenge for transplant as they have invariably consumed alcohol in the preceding weeks. Reluctance to perform transplantation in such patients is often based on the view that they are responsible for their illness and are likely to recommence alcohol use after transplantation [52]. Strict application of the rule requiring six months of sobriety may be disadvantageous to such patients, as 70 to 80% of them die within that period due to non-response to medical therapy [53]. The Lille model facilitates early identification of such patients who are unlikely to respond to medical treatment [5,6]. Although alcoholic hepatitis was an absolute contraindication for placement on the transplant waiting list according to the AASLD and the UK Liver Advisory Group [54,55], the UNOS and the French Consensus Conference do not consider it to be a formal guideline. They rather recommend a balanced analysis of the individual patient [9]. Using the UNOS database, evidence supporting the benefit of LT for severe AH has been reported in a study of 55 patients who were transplanted for AH compared with 165 matched

patients transplanted for alcoholic cirrhosis. The AH patients had similar five-year liver graft survival rates at 85% compared to 87% in those transplanted for alcoholic cirrhosis with $P=0.21$. Patient survival in the AH versus alcoholic cirrhosis group was 91% versus 89%, $P=0.35$. This suggests that LT may be effective in a highly selected cohort of patients with AH [56].

Findings from a European multicenter study suggested that selected group of patients suffering from their first episode of severe AH who failed medical treatment but received a favorable psychosocial assessment, had excellent survival and low frequency of harmful drinking after LT [4]. Likewise, Mathurin et al., compared patients with severe AH nonresponsive to steroids (defined as ≥ 0.45 Lille score) who underwent early OLT (within nine days of listing from first episode of severe AH) to patients who did not undergo OLT in a case-controlled French study. At six months, the patient survival rate amongst the early-transplanted group was higher compared to the control group (83.3% vs. 44%). Among the non-transplanted, 50% to 90% deaths occurred within first two months. This benefit of early transplantation was maintained through two years of follow-up [56]. Thus, early OLT should be considered as one of the treatment options in select groups of patients with AH who are unresponsive to medical therapy and unlikely to survive to complete the six-month abstinence period, but are otherwise suitable candidates for transplantation. [43,56-61]. However, the above studies had few inherent limitations including post-transplant infection, significant perioperative transplant mortality and a finite risk of relapse to drinking, making the overall benefit of early transplantation questionable and non-generalizable to all patients with AH.

Conclusion

In light of the available literature, we may need to reconsider the concept of an approved abstinence period as the only condition for transplant eligibility as well as the fact that alcoholic hepatitis is a contraindication for transplantation [62]. This condition of an abstinence period may also delay listing of a considerable number of candidates for transplantation with a low probability of relapse [63-70]. Further, the duration of abstinence before transplantation is a poor predictor of relapse to drinking and stringent selection of candidates can result in a low rate of relapse. Early liver transplantation may be an appropriate rescue option for selected patients whose first episode of severe alcoholic hepatitis is not responsive to medical therapy, after careful assessment of their addiction profile. Existing data clearly show that LT is a potential treatment option for the group of patients with severe AH who continue to deteriorate despite intensive medical treatment. Further, six months of abstinence does not affect recidivism after OLT. In order to pick the patients who would gain the most benefit, we need to evolve the best criteria to categorize candidates with the least risk of recidivism to harmful drinking, for the optimal utilization of available organs in the setting of AH, in the same way as is being done for acute liver failure secondary to other etiologies.

Take home message

1. Large prospective studies are required to provide guidelines for abstinence prior to OLT in alcoholic hepatitis patients who have failed medical therapy or are at high risk of death. In addition, it is equally important to deal with pre-existing psychiatric conditions before and after OLT to provide unrelenting support to prevent relapse and achieve sustained abstinence.

2. As six months of abstinence does not completely affect recidivism after OLT, pursuing the best available criteria to categorize and stratify candidates with the least risk of recidivism to harmful drinking is desired for the optimal utilization of available organs for patients with severe alcoholic hepatitis.

3. Abstinence should not be the only deciding factor for OLT since many patients present beyond the chance for natural liver recovery and transplant is their only option.

4. Existing data shows that liver transplant is a potential treatment option for the specific group of patients with severe AH who continue to deteriorate despite intensive medical treatment.

References

1. Burra P, Senzolo M, Adam R, Delvart V, Karam V, et al. (2010) Liver transplantation for alcoholic liver disease in Europe: a study from the ELTR (European Liver Transplant Registry). *Am J Transplant* 10: 138-148.
2. Burroughs AK, Sabin CA, Rolles K, Delvart V, Karam V, et al. (2006) 3-month and 12-month mortality after first liver transplant in adults in Europe: predictive models for outcome. *Lancet* 367: 225-232.
3. Beresford TP, Everson GT (2000) Liver transplantation for alcoholic liver disease: bias, beliefs, 6-month rule, and relapse--but where are the data? *Liver Transpl* 6: 777-778.
4. Castel H, Moreno C, Antonini T, Duclos-Vallee J, Dumortier J, et al. (2009) Early transplantation improves survival of non-responders to steroids in severe alcoholic hepatitis: A challenge to the 6 month rule of abstinence. *Hepatology* 4: 307A-308A.
5. Louvet A, Naveau S, Abdelnour M, Ramond MJ, Diaz E, et al. (2007) The Lille model: a new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated with steroids. *Hepatology* 45: 1348-1354.
6. Louvet A, Wartel F, Castel H, Dharancy S, Hollebecque A, et al. (2009) Early transplantation improves survival of non-responders to steroids: early response to therapy is the key factor. *Gastroenterology* 137: 541-548.
7. Everhart JE, Beresford TP (1997) Liver transplantation for alcoholic liver disease: a survey of transplantation programs in the United States. *Liver Transpl Surg* 3: 220-226.
8. Foster PF, Fabrega F, Karademir S, Sankary HN, Mital D, et al. (1997) Prediction of abstinence from ethanol in alcoholic recipients following liver transplantation. *Hepatology* 25: 1469-1477.
9. O'Shea RS, Dasarathy S, McCullough AJ; Practice Guideline Committee of the American Association for the Study of Liver Diseases; Practice Parameters Committee of the American College of Gastroenterology (2010) Alcoholic liver disease. *Hepatology* 51: 307-328.
10. Maddrey WC, Boitnott JK, Bedine MS, Weber FL Jr, Mezey E, et al. (1978) Corticosteroid therapy of alcoholic hepatitis. *Gastroenterology* 75: 193-199.
11. Naveau S, Giraud V, Borotto E, Aubert A, Capron F, et al. (1997) Excess weight risk factor for alcoholic liver disease. *Hepatology* 25: 108-111.
12. Mendenhall CL, Moritz TE, Roselle GA, Morgan TR, Nemchausk BA, et al. (1993) A study of oral nutritional support with oxandrolone in malnourished patients with alcoholic hepatitis: results of a Department of Veterans Affairs cooperative study. *Hepatology* 17: 564-576.
13. Mendenhall CL (1981) Alcoholic hepatitis. *Clin Gastroenterol* 10: 417-441.
14. Lischner MW, Alexander JF, Galambos JT (1971) Natural history of alcoholic hepatitis. I. The acute disease. *Am J Dig Dis* 16: 481-494.
15. Ceccanti M, Attili A, Balducci G, Attilia F, Giacomelli S, et al. (2006) Acute alcoholic hepatitis. *J Clin Gastroenterol* 40: 833-841.
16. Fujimoto M, Uemura M, Kojima H, Ishii Y, Ann T, et al. (1999) Prognostic factors in severe alcoholic liver injury. *Nara Liver Study Group. Alcohol Clin Exp Res* 23: 33S-38S.

17. Maher JJ (2002) Treatment of alcoholic hepatitis. *J Gastroenterol Hepatol* 17: 448-455.
18. Bird GL, Williams R (1988) Factors determining cirrhosis in alcoholic liver disease. *Mol Aspects Med* 10: 97-105.
19. Mathurin P, Mendenhall CL, Carithers RL Jr, Raymond MJ, Maddrey WC, et al. (2002) Corticosteroids improve short term survival in patients with severe alcoholic hepatitis (AH): individual data analysis of the last three randomized placebo controlled double blind trials of corticosteroids in severe AH. *J Hepatol* 36: 480-487.
20. Sheth M, Riggs M, Patel T (2002) Utility of the Mayo End-Stage Liver Disease (MELD) score in assessing prognosis of patients with alcoholic hepatitis. *BMC Gastroenterol* 2: 2.
21. Dunn W, Jamil LH, Brown LS, Wiesner RH, Kim WR, et al. (2005) MELD accurately predicts mortality in patients with alcoholic hepatitis. *Hepatology* 41: 353-358.
22. Srikureja W, Kyulo NL, Runyon BA, Hu KQ (2005) MELD score is a better prognostic model than Child-Turcotte-Pugh score or Discriminant Function score in patients with alcoholic hepatitis. *J Hepatol* 42: 700-706.
23. Yang AL, Vadhavkar S, Singh G, Omary MB (2008) Epidemiology of alcohol-related liver and pancreatic disease in the United States. *Arch Intern Med* 168: 649-656.
24. Moss AH, Siegler M (1991) Should alcoholics compete equally for liver transplantation? *JAMA* 265: 1295-1298.
25. Neuberger J, Adams D, MacMaster P, Maidment A, Speed M (1998) Assessing priorities for allocation of donor liver grafts: survey of public and clinicians. *BMJ* 317: 172-175.
26. Surman OS, Cosimi AB, DiMartini A (2009) Psychiatric care of patients undergoing organ transplantation. *Transplantation* 87: 1753-1761.
27. (1984) Anonymous Hepatology. National Institutes of Health Consensus Development Conference on Liver Transplantation. Sponsored by the National Institute of Arthritis, Diabetes, and Digestive and Kidney Diseases and the National Institutes of Health Office of Medical Applications of Research 4: 1S-110S.
28. Tome S, Lucey MR (2003) Timing of liver transplantation in alcoholic cirrhosis. *J Hepatol* 39: 302-307.
29. Tandon P, Goodman KJ, Ma MM, Wong WW, Mason AL, et al. (2009) A shorter duration of pre-transplant abstinence predicts problem drinking after liver transplantation. *Am J Gastroenterol* 104: 1700-1706.
30. Lim JK, Keeffe EB (2004) Liver transplantation for alcoholic liver disease: current concepts and length of sobriety. *Liver Transpl* 10: S31-38.
31. Webb K, Shepherd L, Day E, Masterton G, Neuberger J (2006) Transplantation for alcoholic liver disease: report of a consensus meeting. *Liver Transpl* 12: 301-305.
32. Bathgate AJ, UK Liver Transplant Units (2006) Recommendations for alcohol-related liver disease. *Lancet* 367: 2045-2046.
33. Anantharaju A, Van Thiel DH (2003) Liver transplantation for alcoholic liver disease. *Alcohol Res Health* 27: 257-268.
34. Veldt BJ, Lainé F, Guillygomarc'h A, Lauvin L, Boudjema K, et al. (2002) Indication of liver transplantation in severe alcoholic liver cirrhosis: quantitative evaluation and optimal timing. *J Hepatol* 36: 93-98.
35. Platz KP, Mueller AR, Spree E, Schumacher G, Nüssler NC, et al. (2000) Liver transplantation for alcoholic cirrhosis. *Transpl Int* 13 Suppl 1: S127-130.
36. Karim Z, Intaraprasong P, Scudamore CH, Erb SR, Soos JG, et al. (2010) Predictors of relapse to significant alcohol drinking after liver transplantation. *Can J Gastroenterol* 24: 245-250.
37. Jauhar S, Talwalkar JA, Schneekloth T, Jowsey S, Wiesner RH, et al. (2004) Analysis of factors that predict alcohol relapse following liver transplantation. *Liver Transpl* 10: 408-411.
38. Kelly M, Chick J, Gribble R, Gleeson M, Holton M, et al. (2006) Predictors of relapse to harmful alcohol after orthotopic liver transplantation. *Alcohol Alcohol* 41: 278-283.
39. Foster PF, Fabrega F, Karademir S, Sankary HN, Mital D, et al. (1997) Prediction of abstinence from ethanol in alcoholic recipients following liver transplantation. *Hepatology* 25: 1469-1477.
40. Anand AC, Ferraz-Neto BH, Nightingale P, Mirza DF, White AC, et al. (1997) Liver transplantation for alcoholic liver disease: evaluation of a selection protocol. *Hepatology* 25: 1478-1484.
41. Mackie J, Groves K, Hoyle A, Garcia C, Garcia R, et al. (2001) Orthotopic liver transplantation for alcoholic liver disease: a retrospective analysis of survival, recidivism, and risk factors predisposing to recidivism. *Liver Transpl* 7: 418-427.
42. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, et al. (1996) Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. *N Engl J Med* 334: 693-699.
43. Mathurin P, O'Grady J, Carithers RL, Phillips M, Louvet A, et al. (2011) Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis: meta-analysis of individual patient data. *Gut* 60: 255-260.
44. Coffin PO, Sharpe BA (2007) Cause of death in alcoholic hepatitis. *J Hosp Med* 2: 51-52.
45. Yu CH, Xu CF, Ye H, Li L, Li YM (2010) Early mortality of alcoholic hepatitis: a review of data from placebo-controlled clinical trials. *World J Gastroenterol* 16: 2435-2439.
46. Imperiale TF, McCullough AJ (1990) Do corticosteroids reduce mortality from alcoholic hepatitis? A meta-analysis of the randomized trials. *Ann Intern Med* 113: 299-307.
47. Christensen E, Gluud C (1995) Glucocorticoids are ineffective in alcoholic hepatitis: a meta-analysis adjusting for confounding variables. *Gut* 37: 113-118.
48. Parker R, Armstrong MJ, Corbett C, Rowe IA, Houlihan DD (2013) Systematic review: pentoxifylline for the treatment of severe alcoholic hepatitis. *Aliment Pharmacol Ther* 37: 845-854.
49. European Association for the Study of Liver (2012) EASL clinical practical guidelines: management of alcoholic liver disease. *J Hepatol* 57: 399-420.
50. Whitfield K, Rambaldi A, Wetterslev J, Gluud C (2009) Pentoxifylline for alcoholic hepatitis. *Cochrane Database Syst Rev* : CD007339.
51. Louvet A, Diaz E, Dharancy S, Coevoet H, Texier F, et al. (2008) Early switch to pentoxifylline in patients with severe alcoholic hepatitis is inefficient in non-responders to corticosteroids. *J Hepatol* 48: 465-470.
52. Shawcross DL, O'Grady JG (2010) The 6-month abstinence rule in liver transplantation. *Lancet* 376: 216-217.
53. Lucey MR, Brown KA, Everson GT, Fung JJ, Gish R, et al. (1997) Minimal criteria for placement of adults on the liver transplant waiting list: a report of a national conference organized by the American Society of Transplant Physicians and the American Association for the Study of Liver Diseases. *Liver Transpl Surg* 3: 628-637.
54. Bathgate AJ, UK Liver Transplant Units (2006) Recommendations for alcohol-related liver disease. *Lancet* 367: 2045-2046.
55. Mathurin P, Moreno C, Samuel D, Dumortier J, Salleron J, et al. (2011) Early liver transplantation for severe alcoholic hepatitis. *N Engl J Med* 365: 1790-1800.
56. Dunn W, Jamil LH, Brown LS, Wiesner RH, Kim WR, et al. (2005) MELD accurately predicts mortality in patients with alcoholic hepatitis. *Hepatology* 41: 353-358.
57. Forrest EH, Evans CD, Stewart S, Phillips M, Oo YH, et al. (2005) Analysis of factors predictive of mortality in alcoholic hepatitis and derivation and validation of the Glasgow alcoholic hepatitis score. *Gut* 54: 1174-1179.
58. Srikureja W, Kyulo NL, Runyon BA, Hu KQ (2005) MELD score is a better prognostic model than Child-Turcotte-Pugh score or Discriminant Function score in patients with alcoholic hepatitis. *J Hepatol* 42: 700-706.
59. Lucey MR, Mathurin P, Morgan TR (2009) Alcoholic hepatitis. *N Engl J Med* 360: 2758-2769.
60. Lucey MR, Brown KA, Everson GT, Fung JJ, Gish R, et al. (1997) Minimal criteria for placement of adults on the liver transplant waiting list: a report of a national conference organized by the American Society of Transplant Physicians and the American Association for the Study of Liver Diseases. *Liver Transpl Surg* 3: 628-637.

61. Miguet M, Monnet E, Vanlemmens C, Gache P, Messner M, et al. (2004) Predictive factors of alcohol relapse after orthotopic liver transplantation for alcoholic liver disease. *Gastroenterol Clin Biol* 28: 845-851.
62. Bravata DM, Olkin I, Barnato AE, Keeffe EB, Owens DK (2001) Employment and alcohol use after liver transplantation for alcoholic and nonalcoholic liver disease: a systematic review. *Liver Transpl* 7: 191-203.
63. Jaurigue MM, Cappell MS (2014) Therapy for alcoholic liver disease. *World J Gastroenterol* 20: 2143-2158.
64. Abenavoli L, Milic N, Rouabhia S, Addolorato G (2014) Pharmacotherapy of acute alcoholic hepatitis in clinical practice. *World J Gastroenterol* 20: 2159-2167.
65. Singal AK, Kamath PS, Gores GJ, Shah VH (2014) Alcoholic hepatitis: current challenges and future directions. *Clin Gastroenterol Hepatol* 12: 555-564.
66. Stickel F, Seitz HK (2013) Update on the management of alcoholic steatohepatitis. *J Gastrointest Liver Dis* 22: 189-197.
67. Sohail U, Satapathy SK (2012) Diagnosis and management of alcoholic hepatitis. *Clin Liver Dis* 16: 717-736.
68. Berlakovich GA (2014) Challenges in transplantation for alcoholic liver disease. *World J Gastroenterol* 20: 8033-8039.
69. Schaubel DE, Guidinger MK, Biggins SW, Kalbfleisch JD, Pomfret EA, et al. (2009) Survival benefit-based deceased-donor liver allocation. *Am J Transplant* 9: 970-981.
70. Dutkowski P, Linecker M, DeOliveira ML, Müllhaupt B, Clavien PA (2015) Challenges to liver transplantation and strategies to improve outcomes. *Gastroenterology* 148: 307-323.